EQS-News
CompuGroup Medical Annual General Meeting: Shareholders approve dividend doubling to EUR 1.00
- Shareholders approve dividend doubling to EUR 1.00
- High approval rates for capital measures
- Focus on data-based solutions and artificial intelligence
EQS-News: CompuGroup Medical SE & Co. KGaA / Key word(s): AGM/EGM CompuGroup Medical Annual General Meeting: Shareholders approve dividend doubling to EUR 1.00 |
- Acts of the governing boards formally approved
- Dividend proposal of EUR 1.00 confirmed
- High approval rates for capital measures
- Focus on data-based solutions and artificial intelligence
Koblenz - The shareholders of CompuGroup Medical SE & Co. KGaA (CGM) approved the dividend proposal of the General Partner, the Supervisory Board and the Managing Directors at the e-health group's virtual Annual General Meeting (AGM) on May 22, 2024. As a result, a dividend of EUR 1.00 per share will be paid for the financial year 2023, twice as much as in the previous year. This corresponds to a payout of around EUR 51.7 million. The shareholders also approved all proposed capital measures by majorities of more than 90 percent such as the enactment of authorized capital, the authorization to issue convertible bonds and share options or the authorization to acquire and use treasury shares.
The shareholders approved the annual financial statements of CompuGroup Medical SE & Co. KGaA for 2023 and passed the remuneration report for 2023. The actions of the General Partner of CompuGroup Medical SE & Co. KGaA and the members of the Supervisory Board were formally approved.
All other items on the agenda were also approved by the shareholders with a large majority. A total of around 79 percent of the share capital of CompuGroup Medical SE & Co. KGaA was represented at the Annual General Meeting. The speeches by CEO Michael Rauch and CFO Daniela Hommel, who has been in office since February 1, were published beforehand online. A video replay of both speeches will be made avaailable subsequently on the company's website.